Conditions: Schizophrenia
Keywords: schizophrenia antipsychotics dopamine D3/D2 antagonist
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 34
Healthy volunteers: no

Brief summary:
The purpose of this study is to assess the safety, pharmacokinetics and efficacy of 3 fixed doses of MP-214 orally administered once daily to patients with schizophrenia. MP-214 tablets will be administered to patients starting at an initial dose, followed by up-titration to a fixed dose (low, medium or high) for 14 days.

Detailed description:

Arms:
arm 1: None arm 2: None arm 3: None

Interventions: intervention 1: Cariprazine 3 mg intervention 2: Cariprazine 6 mg intervention 3: Cariprazine 12.5 mg
Intervention descriptions: intervention 1: None intervention 2: None intervention 3: None

Protocol document: